Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Kairos Pharma Ltd KAPA

Healthcare Biotechnology
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to... see more

Current News (NYSEAM:KAPA)

Kairos Pharma Provides Shareholder Update

Business Wire November 4, 2025

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Business Wire October 20, 2025

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Business Wire October 7, 2025

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Business Wire September 18, 2025

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Business Wire September 11, 2025

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Business Wire September 3, 2025

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Business Wire September 2, 2025

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Business Wire July 16, 2025

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Business Wire July 15, 2025
View More News ››

Opinion & Analysis (NYSEAM:KAPA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:KAPA)

Using technical analysis for this stock.

It is signalling a continuing uptrend for shareholders today,so good luck to all of you guys
coolfooldumbguy - September 2, 2025

Great Speculation

KAPA looks to be putting bottom in. This could be the best specultive buy of the year. Very low share count, very explosive revenue...
Keepdigging - May 8, 2025

It was a buy for me this morning

At $1.35 cents per share.It is looking good for shareholders.
coolfooldumbguy - January 13, 2025

First to post here

Bump higher today
Tradinghands - November 13, 2024
View more Bullboard ››

Eshbal Functional Food Inc

Eshbal Functional Food Inc

Eshbal Functional Food Inc. researches, develops, and manufactures food products and dietary supplements Israel, North ...
View More »